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Abstract 
Background: Type 2 diabetes mellitus (T2DM) is often associated with mixed dyslipidaemia, where non‑high‑
density lipoprotein cholesterol (non‑HDL‑C) levels may more closely align with cardiovascular risk than low‑density 
lipoprotein cholesterol (LDL‑C). We describe the design and rationale of the ODYSSEY DM‑DYSLIPIDEMIA study that 
assesses the efficacy and safety of alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, versus 
lipid‑lowering usual care in individuals with T2DM and mixed dyslipidaemia at high cardiovascular risk with non‑
HDL‑C inadequately controlled despite maximally tolerated statin therapy. For the first time, atherogenic cholesterol‑
lowering with a PCSK9 inhibitor will be assessed with non‑HDL‑C as the primary endpoint with usual care as the 
comparator.
Methods: DM‑DYSLIPIDEMIA is a Phase 3b/4, randomised, open‑label, parallel group, multinational study that 
planned to enrol 420 individuals. Main inclusion criteria were T2DM and mixed dyslipidaemia (non‑HDL‑C ≥100 mg/dl 
[≥2.59 mmol/l], and triglycerides ≥150 and <500 mg/dl [≥1.70 and <5.65 mmol/l]) with documented atherosclerotic 
cardiovascular disease or ≥1 additional cardiovascular risk factor. Participants were randomised (2:1) to alirocumab 
75 mg every 2 weeks (Q2W) or lipid‑lowering usual care on top of maximally tolerated statin (or no statin if intolerant). 
If randomised to usual care, investigators were able to add their pre‑specified choice of one of the following to the 
patient’s current statin regimen: ezetimibe, fenofibrate, omega‑3 fatty acids or nicotinic acid, in accordance with local 
standard‑of‑care. Alirocumab‑treated individuals with non‑HDL‑C ≥100 mg/dl at week 8 will undergo a blinded dose 
increase to 150 mg Q2W at week 12. The primary efficacy endpoint is non‑HDL‑C change from baseline to week 24 
with alirocumab versus usual care; other lipid levels (including LDL‑C), glycaemia‑related measures, safety and toler‑
ability will also be assessed. Alirocumab will be compared to fenofibrate in a secondary analysis.
Results: Recruitment completed with 413 individuals randomised in 14 countries worldwide. Results of this trial are 
expected in the second quarter of 2017.
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Background
Cardiovascular disease is a significant cause of morbid-
ity and mortality in persons with type 2 diabetes mel-
litus (T2DM) [1]. Individuals with T2DM often have 
elevated levels of non-high-density lipoprotein choles-
terol (non-HDL-C), triglycerides (TGs), and small, dense 
low-density lipoprotein (LDL), which further increase 
their cardiovascular risk. Mixed dyslipidaemia is com-
monly associated with insulin resistance, which accounts 
for increased hepatic production of very low-density 
lipoprotein (VLDL), enhanced intestinal production of 
chylomicrons, and reduced hepatic clearance of TG-rich 
lipoproteins (TRL) [2]. The management of mixed dys-
lipidaemia is a persistent challenge in clinical practice [3].
The relationship between LDL cholesterol (LDL-C) and 
cardiovascular risk is well established [4]. However, non-
HDL-C, which can easily be calculated from a routine 
lipid panel by subtracting HDL-C from total cholesterol 
(TC) [5], is considered a better predictor of cardiovascu-
lar risk, particularly in individuals with T2DM and mixed 
dyslipidaemia [6–8]. Non-HDL-C has been proposed 
as a therapeutic target for mixed dyslipidaemia since it 
encompasses all circulating atherogenic cholesterol car-
ried by apolipoprotein (Apo) B-containing lipoprotein 
particles, like TRL, including VLDL, intermediate-den-
sity lipoprotein (IDL), LDL and lipoprotein(a) [Lp(a)]. 
The National Lipid Association recommendations indi-
cate non-HDL-C as a co-primary, but superior, treat-
ment target with LDL-C [9]. Recent European guidelines 
[4, 10] recommend non-HDL-C as a practical alternative 
treatment target. However, the effect of novel lipid-low-
ering treatments on this parameter is still poorly studied.
Most guidelines/consensus statements suggest a non-
HDL-C target of 30  mg/dl above target LDL-C levels. 
Therefore, for individuals with diabetes mellitus (DM) at 
very-high or high cardiovascular risk who have LDL-C 
goals of <70 or <100 mg/dl, respectively, the recommended 
non-HDL-C levels are <100 or <130 mg/dl [9–12].
Maximally tolerated statin therapy is commonly used 
to manage mixed dyslipidaemia, particularly with the 
goal of reducing LDL-C and non-HDL-C levels. Sig-
nificant reductions in cardiovascular events have been 
observed in individuals with DM treated with statins 
[13]. However, real-world studies often report under-
utilisation of statins and sub-optimal dosing in high-risk 
patients [14, 15]. Additional lipid-lowering therapies are 
used in conjunction with statins to address mixed dys-
lipidaemia, including ezetimibe, fibrates, nicotinic acid 
and omega-3 fatty acids. Although these additional thera-
pies have not definitively demonstrated cardiovascular 
outcome benefits in several large randomised trials, in a 
post hoc subgroup analysis, fibrates have been associated 
with an apparent reduction in cardiovascular events in 
patients with mixed dyslipidaemia [16]. Fibrate therapy 
was most beneficial when TG levels were lowered, par-
ticularly in individuals with high baseline TG levels [16, 
17]. Despite these treatment options, many individuals 
with DM continue to have persistent lipid abnormalities 
[18–20], and are therefore exposed to residual cardiovas-
cular risk [21–23].
Alirocumab is a fully human monoclonal antibody that 
binds to and inhibits proprotein convertase subtilisin/
kexin type 9 (PCSK9), a key regulator of plasma LDL-C 
metabolism. Alirocumab is approved in many countries, 
including the USA and across Europe, for the manage-
ment of patients with hypercholesterolaemia on maxi-
mally tolerated statin therapy. As demonstrated in the 
ODYSSEY Phase 3 clinical studies, alirocumab reduces 
LDL-C levels by up to 60%, both alone and in combina-
tion with statin and other lipid-lowering therapies, in 
patients with dyslipidaemia [24]. In contrast to boco-
cizumab (a murine-derived, humanised monoclonal 
antibody to PCSK9 that was recently discontinued from 
clinical development due to the attenuation of LDL-C 
lowering over time and higher rates of immunogenic-
ity) [25, 26], LDL-C reductions on alirocumab did not 
decrease over time and very low rates of immunogenic-
ity were observed. Such evidence suggests differences in 
immunogenicity potential for murine-derived antibodies 
humanised by in vitro artificial engineering, versus fully 
human antibodies that were produced with mice with 
genetically humanised immune systems [27].
In addition to LDL-C lowering, alirocumab signifi-
cantly reduces non-HDL-C, Apo B and Lp(a), and trends 
for reduction in TGs, along with modest increases in 
HDL-C and Apo A-1, were also observed [24]. Data from 
a post hoc analysis of the ODYSSEY LONG TERM trial 
have been promising, with early indication of a reduced 
rate of cardiovascular events with alirocumab [28]. The 
benefit of alirocumab on cardiovascular morbidity and 
Conclusions: ODYSSEY DM‑DYSLIPIDEMIA will provide information on the efficacy and safety of alirocumab versus 
lipid‑lowering usual care in individuals with T2DM and mixed dyslipidaemia at high cardiovascular risk using non‑HDL‑
C as the primary efficacy endpoint.
Trial registration NCT02642159 (registered December 24, 2015)
Keywords: Alirocumab, PCSK9, Diabetes, Mixed dyslipidaemia, Non‑HDL‑C, ODYSSEY
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mortality will be assessed in the ongoing ODYSSEY 
OUTCOMES trial (NCT01663402), which will include 
over 18,000 patients randomised within 1 year post acute 
coronary syndrome, many of whom also have DM [29].
Sub-analyses of individual and pooled data from 
ODYSSEY Phase 3 studies showed a similar efficacy and 
safety profile in individuals receiving alirocumab with 
and without DM [30, 31], with no effect on glycaemic 
control [32]. In a pooled subgroup analysis of five Phase 
3 trials of individuals with DM and mixed dyslipidae-
mia, alirocumab substantially improved LDL-C and non-
HDL-C levels versus placebo, with similar results and 
safety profiles observed when compared with individu-
als without mixed dyslipidaemia [33]. While this analy-
sis addresses an important clinical question, it remains 
unknown what is the best treatment strategy to manage 
lipid abnormalities and reduce cardiovascular burden in 
individuals with DM and mixed dyslipidaemia on maxi-
mally tolerated statin therapy. Furthermore, the efficacy 
and safety of alirocumab in this patient population has 
yet to be assessed in a dedicated study in the ODYSSEY 
programme, nor has any other clinical trial studying 
PCSK9 inhibitors utilised non-HDL-C as the primary 
endpoint.
Here, we describe the design and rationale for the 
ODYSSEY DM-DYSLIPIDEMIA study, which evalu-
ates the superiority of alirocumab versus lipid-lowering 
usual care, utilising non-HDL-C as the primary efficacy 
endpoint, in individuals with T2DM and mixed dyslipi-
daemia at high cardiovascular risk with non-HDL-C not 
adequately controlled with maximally tolerated statin 
therapy. Usual care included optional addition of one of 
the following lipid-lowering therapies: ezetimibe, fenofi-
brate, omega-3 fatty acids or nicotinic acid. Findings 
from this head-to-head study of alirocumab versus lipid-
lowering usual care will inform clinical decision-making 
beyond maximally tolerated statin therapy. In a second-
ary analysis, superiority of alirocumab versus fenofibrate 
on non-HDL-C (and all other efficacy endpoints meas-
ured in the primary analysis versus usual care) will also 
be assessed.
Methods
Study design
ODYSSEY DM-DYSLIPIDEMIA (ClinicalTrials.gov 
identifier: NCT02642159) is a Phase 3b/4, randomised, 
open-label, parallel group, multi-centre, multinational 
clinical trial. The study evaluates the efficacy and safety of 
alirocumab versus lipid-lowering usual care in the reduc-
tion of non-HDL-C in individuals with T2DM and mixed 
dyslipidaemia at high cardiovascular risk with non-HDL-
C not adequately controlled with maximally tolerated 
statin therapy (Fig.  1). The planned population for this 
study was 420 individuals. This trial began recruitment in 
March 2016 with main study results expected in the sec-
ond quarter of 2017.
This clinical trial is being performed in accordance 
with the ethical principles outlined at the 18th World 
Medical Assembly (Helsinki, 1964) and all applicable 
amendments by the World Medical Assemblies and 
Fig. 1 Study design. EOT end of treatment, LLT lipid‑lowering therapy, MTD maximally tolerated dose, non‑HDL‑C non‑high‑density lipoprotein cho‑
lesterol, Q2W every 2 weeks, R randomisation, W week. aFirst study drug administration. As a principle, randomisation should occur after signature of 
the informed consent form and just before the first dosing of the study drug (i.e. alirocumab or usual care). The randomisation day is always day 1. 
Randomisation was stratified by the investigator’s selection of usual care therapy prior to randomisation. Phone call visits are indicated in italics
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International Conference Harmonization Guidelines 
for Good Clinical Practice. Institutional review board or 
independent ethics committee approval of the protocols 
and informed consent forms from each study site (Addi-
tional file 1: Appendix S1) have been obtained, and writ-
ten informed consent has been obtained from all study 
participants.
Inclusion and exclusion criteria
Inclusion and exclusion criteria are shown in Table 1. A 
full list and details of inclusion and exclusion criteria can 
be found in Additional file 1: Appendix S2.
This trial enrolled adults with T2DM and mixed 
dyslipidaemia (defined as non-HDL-C  ≥100  mg/
dl [2.59  mmol/l], and TG  ≥150  mg/dl [1.70  mmol/l] 
and <500 mg/dl [5.65 mmol/l] at the screening visit) that 
was not adequately controlled with stable maximally tol-
erated statin therapy for ≥4 weeks prior to the screening 
visit without other lipid-lowering therapies. Individuals 
were required to have documented history of athero-
sclerotic cardiovascular disease (defined as established 
coronary heart disease, peripheral arterial disease or 
ischaemic stroke), or at least one additional cardiovas-
cular risk factor in individuals without atherosclerotic 
cardiovascular disease. The maximally tolerated dose of 
statin was defined as the highest registered dose/regimen 
tolerated by the individual based on the investigator’s 
judgment. Individuals with statin intolerance (as judged 
by the investigator) documented in medical history, who 
as a result are no longer on statin therapy, were also eligi-
ble to enrol in this study.
Study participants will continue on a stable cholesterol-
lowering diet throughout the study, and must be on sta-
ble anti-hyperglycaemic therapy (including non-insulin 
anti-hyperglycaemic agents and insulin) for  ≥3  months 
prior to the screening visit and during the study; changes 
to anti-hyperglycaemic therapy are allowed only if clini-
cally needed.
Individuals were excluded if they were on any non-
statin lipid-lowering therapies (including any over-the-
counter products/nutraceuticals known to impact lipids) 
within 4 weeks prior to the screening visit or during the 
screening period, had body mass index >45 kg/m2 or had 
glycated haemoglobin  (HbA1c) ≥9% at the screening visit.
Study procedures
Individuals were assessed for eligibility during a screen-
ing period of up to 3 weeks, followed by randomisation 
to alirocumab or usual care for a 24-week treatment 
period. After completing the treatment period, study par-
ticipants entered a safety observation period of 8 weeks 
(Fig.  1). On-site clinical assessments are scheduled at 
weeks—3 (screening), 0 (randomisation), 8, 12, 20 and 24 
(end-of-treatment visit), with additional phone visits at 
weeks 4 and 32.
Eligible individuals were randomised 2:1 to open-
label treatment with alirocumab or usual care. At ran-
domisation, treatment was allocated using a centralised 
treatment allocation system (interactive voice- or web-
response system, depending on the study site preference). 
To ensure balanced treatment groups, randomisation was 
stratified by the investigator’s choice of usual care ther-
apy, which was pre-specified prior to randomisation.
Usual care includes the option to continue on maxi-
mally tolerated statin therapy without the addition of 
another lipid-lowering therapy at randomisation, or 
with the addition of one of the following lipid-lowering 
treatments at randomisation (based on the investiga-
tor’s pre-specified choice for that individual participant): 
ezetimibe, fenofibrate, omega-3 fatty acids or nicotinic 
acid. The pharmaceutical form, dose and number of units 
per administration, as well as the timing of dosing of the 
usual care treatment, will be determined by the investi-
gator and prescribed as per the investigator’s usual prac-
tice in accordance with local standard-of-care. The only 
fibrate that is allowed in this study is fenofibrate. Usual 
care treatment should be started no later than 7  days 
from the day of randomisation and should continue for 
the entire 24-week treatment period. The treatment 
Table 1 Inclusion and exclusion criteria
ASCVD atherosclerotic cardiovascular disease, BMI body mass index, 
CHD coronary heart disease, CKD chronic kidney disease, HbA1c glycated 
haemoglobin, MI myocardial infarction, non‑HDL‑C non‑high‑density lipoprotein 
cholesterol, PAD peripheral arterial disease, TG triglyceride, UA unstable angina
a History of CHD: acute MI, silent MI, UA, coronary revascularisation procedure 
or clinically significant CHD diagnosed by invasive or non‑invasive testing
b Cardiovascular risk factors: hypertension, current smoker, aged ≥45 years 
(men) and ≥55 years (women), history of micro/macroalbuminuria or diabetic 
retinopathy, family history of premature CHD, low HDL‑C, documented CKD
Inclusion criteria
 Aged ≥18 years or legal age of majority at screening visit, whichever is 
greater
 ASCVD (including  CHDa, documented PAD or previous ischaemic 
stroke) and/or ≥1 additional cardiovascular risk  factorb
 Stable anti‑hyperglycaemic treatment (including insulin)
 Stable, maximally tolerated dose/regimen of statin for at least 4 weeks 
prior to screening without other lipid‑lowering therapy
 Non‑HDL‑C ≥100 mg/dl (2.59 mmol/l)
 TG ≥150 and <500 mg/dl (≥1.70 and <5.65 mmol/l)
 No weight variation >5 kg within 3 months
Exclusion criteria
 HbA1c ≥9%
 Use of any lipid‑lowering therapy (other than statin) or over‑the‑coun‑
ter product/nutraceuticals known to impact lipids within 4 weeks 
prior to screening
 BMI >45 kg/m2
 Alcohol consumption >two standard alcoholic drinks/day
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strategy implemented post randomisation will remain 
unchanged throughout the study.
For individuals randomised to receive alirocumab 
treatment, alirocumab is administered subcutaneously 
with a starting dose of 75 mg every 2 weeks (Q2W) for 
24 weeks, with blinded dose increase to 150 mg Q2W at 
week 12 if non-HDL-C is ≥100  mg/dl (2.59  mmol/l) at 
week 8. Individuals who have non-HDL-C  <100  mg/dl 
(2.59  mmol/l) at week 8 will continue with alirocumab 
75  mg Q2W until the end of the treatment period. All 
study participants will continue to receive maximally tol-
erated statin therapy (or no statin if statin-intolerant).
All lipid results collected after randomisation are 
masked and, unless required for safety reasons, investi-
gators and study participants should not independently 
evaluate lipid values during the course of the study. For 
safety reasons, investigators will be informed of TG lev-
els ≥500 mg/dl (5.65 mmol/l).
Endpoints and assessments
The primary objective of this trial is to demonstrate 
the superiority of alirocumab in comparison with usual 
care in the reduction of non-HDL-C after 24  weeks of 
treatment.
Primary and key secondary endpoints are summarised 
in Table 2.
The primary efficacy endpoint is the percent change in 
non-HDL-C from baseline to week 24, using all values 
regardless of adherence (intent-to-treat [ITT] approach). 
Secondary/other efficacy endpoints include the effect of 
alirocumab versus usual care at weeks 12 and/or 24 on 
other lipid parameters and sub-fractions (including LDL 
particle [LDL-P] size and number; and VLDL, HDL and 
IDL particle number). DM-related endpoints include 
absolute change from baseline to weeks 12 and 24 in 
 HbA1c, fasting plasma glucose (FPG), and the number of 
glucose-lowering agents. Other endpoints include safety 
and tolerability (assessed throughout the study for up to 
32  weeks), an injection-treatment acceptance question-
naire (I-TAQ) at weeks 8 and 24, changes in plasma PCSK9 
levels (assessed at weeks 12 and 24), and development of 
anti-alirocumab antibodies (assessed at weeks 12 and 24).
Blood sampling to determine all lipid parameters, 
 HbA1c and FPG will be performed in the morning, in 
fasting condition (for at least 10–12  h and refrain from 
smoking). Alcohol consumption within 48 h and intense 
physical exercise within 24  h preceding the blood sam-
pling are discouraged.
TC, HDL-C and TG levels will be directly measured 
from blood samples by the central laboratory at all 
clinic visits. Non-HDL-C will be calculated by subtract-
ing HDL-C from TC. LDL-C will be both determined 
(via beta quantification) by the central laboratory and 
Table 2 Primary and key secondary endpoints
AESI adverse event of special interest, Apo apolipoprotein, BMI body mass index, 
FPG fasting plasma glucose, HbA1c glycated haemoglobin, HDL‑C high‑density 
lipoprotein cholesterol, IDL intermediate‑density lipoprotein, I‑TAQ injection‑
treatment acceptance questionnaire, ITT intent‑to‑treat, LDL‑C low‑density 
lipoprotein cholesterol, LDL‑P, low‑density lipoprotein particle, Lp(a) lipoprotein 
(a), PCSK9 proprotein convertase subtilisin/kexin type 9, TC total cholesterol, 
TEAE treatment‑emergent adverse event, TG triglyceride, TRL triglyceride‑rich 
lipoprotein, VLDL very low‑density lipoprotein
a All individuals randomised to alirocumab who self‑injected and filled in the 
questionnaire at least once
Primary endpoint
 Change (%) in non‑HDL‑C from baseline to week 24 in ITT population
Key secondary efficacy endpoints
 Change (%) from baseline in ITT population
  Measured LDL‑C at week 24
  Non‑HDL‑C at week 12
  Measured LDL‑C at week 12
  Apo B at week 24
  TC at week 24
  Lp(a) at week 24
  TGs at week 24
  HDL‑C at week 24
  LDL‑P number at week 24
Other efficacy endpoints
 Change (%) from baseline in ITT population
  Calculated LDL‑C at weeks 12 and 24
  Apo B, TC, Lp(a), HDL‑C, TG, and LDL particle number at week 12
  Apo A‑1, Apo C‑III, TRL, LDL‑P size, VLDL, HDL and IDL particle number 
at weeks 12 and 24
  Measured LDL‑C and TG according to baseline TG (<median 
or >median) at weeks 12 and 24
 Patients (%) reaching
  Measured LDL‑C <50, 70 and 100 mg/dl at weeks 12 and 24
  Non‑HDL‑C <80, 100 and 130 mg/dl at weeks 12 and 24
  ≥50% reduction from baseline in measured LDL‑C at weeks 12 and 24
  Apo B <80 mg/dl at weeks 12 and 24
 Absolute change from baseline in Apo B/Apo A‑1, TC/HDL‑C and 
LDL‑C/HDL‑C ratios at weeks 12 and 24
Diabetes‑related endpoints
 Absolute change from baseline to weeks 12 and 24 in ITT population
  HbA1c
  FPG
  Number of glucose‑lowering agents
Safety endpoints
 TEAEs
 AESIs
 Product complaints
 Laboratory data (including microalbuminuria)
 Vital signs (including change in body weight and BMI)
Questionnaire
 Treatment acceptance (I‑TAQ) at weeks 8 and 24 (for alirocumab arm 
 onlya)
Other endpoints
 Total and free PCSK9 levels at baseline, weeks 12 and 24
 Anti‑alirocumab antibodies
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calculated (using the Friedewald formula) at all clinic vis-
its. TRL will be calculated by TC minus HDL-C minus 
LDL-C. Apo B, Apo A-1, Apo C-III and Lp(a) will be 
directly measured by the central laboratory at all visits 
(except weeks 4 and 32). The ratio of Apo B/Apo A-1 will 
be calculated, and lipid sub–fractions (LDL-P size and 
number; and LDL, VLDL, HDL and IDL particle num-
ber) will be measured by nuclear magnetic resonance 
spectroscopy at all visits (except weeks 4 and 32).  HbA1c 
levels will be measured at weeks 0, 12 and 24, and FPG 
levels will be measured at weeks 0, 8, 12 and 24.
Treatment acceptance will be assessed for study partic-
ipants randomised to alirocumab at weeks 8 and 24 using 
the I-TAQ [34], a 22-item validated patient-reported 
outcome measure. Specifically, the I-TAQ assesses 
four domains of treatment acceptance: perceived effi-
cacy (i.e. the patient’s perception of whether their treat-
ment is working), acceptance of side effects, injection 
self-efficacy (i.e. the ability of the patient to perform the 
task asked of them, e.g. self-injection) and injection con-
venience. The I-TAQ also has three summary questions 
measuring overall acceptance.
Safety and tolerability of alirocumab will be assessed 
throughout the study for up to 32 weeks in terms of treat-
ment-emergent adverse events (TEAEs), adverse events 
of special interest (described in the Additional file  1: 
Appendix S3), laboratory parameters, and vital signs.
In a designated secondary analysis, all efficacy end-
points will also be analysed to evaluate the superiority 
of alirocumab versus usual care in patients who were 
intended to receive fenofibrate.
Statistical design and analysis
Sample size determination
A total sample size of 420 individuals (280 alirocumab; 
140 usual care) was calculated to provide sufficient power 
for both the primary analysis and the secondary compari-
son with fenofibrate.
For the primary analysis (alirocumab versus usual care), 
a total sample size of 219 individuals (146 alirocumab; 73 
usual care) is required to achieve 90% power to detect 
a difference in mean percent change in non-HDL-C 
between baseline and week 24 at the 0.025 two-sided sig-
nificance level, assuming that the percent change will be 
39% (standard deviation [SD] 28%) and 24% (SD 30%) in 
the alirocumab and the usual care group, respectively.
For the secondary analysis (alirocumab versus fenofi-
brate), the required total sample size is 42 individuals 
(28 alirocumab; 14 fenofibrate) to achieve 90% power to 
detect a difference in mean percent change in non-HDL-
C between baseline and week 24 at the 0.025 two-sided 
significance level, assuming that the percent change will 
be 7% (SD 25%) in the fenofibrate subgroup [35]. The 
total required sample size of 420 individuals was based on 
the assumption that 10% of study participants will receive 
fenofibrate therapy, derived from investigator clinical 
experience provided during study design development.
Primary analysis
The primary efficacy analysis population is the ITT 
population, defined as all randomised individuals with 
an available baseline non-HDL-C value and at least one 
available non-HDL-C value within one of the analysis 
windows up to week 24.
The percent change from baseline to week 24 in non-
HDL-C levels will be analysed using a mixed-effect model 
with repeated measures (MMRM) approach to account 
for missing data. All available post-baseline data within 
the analysis window (weeks 8–24) will be used. The 
MMRM model will include fixed categorical effects of 
treatment group, time point, randomisation strata, treat-
ment-by-time point interaction, and strata-by-time point 
interaction as well as the continuous fixed covariates of 
baseline non-HDL-C value and baseline value-by-time 
point interaction. Alirocumab will be compared with 
usual care using appropriate contrasts, and the 97.5% 
confidence interval of the difference will be provided.
Secondary analyses
A hierarchical procedure (concerning key secondary end-
points only) will be used to control the type I error and 
handle multiple endpoints. If the primary endpoint anal-
ysis is significant at an alpha level of 2.5%, secondary end-
points will be tested sequentially using the order defined 
in Table 2.
Continuous secondary endpoints anticipated to have 
a normal distribution will be analysed using the same 
MMRM model as for the primary endpoint with the con-
tinuous fixed covariates of corresponding baseline value 
and baseline value-by-time point interaction. Continuous 
secondary endpoints anticipated to have a non-normal 
distribution will be analysed using a multiple imputa-
tion approach for handling of missing values, followed by 
robust regression. Binary secondary endpoints will be 
analysed using multiple imputation approach for han-
dling of missing values followed by logistic regression.
For the analysis of alirocumab versus fenofibrate, sig-
nificance will be claimed at the 2.5% alpha level, and the 
hierarchical procedure will also be used. The comparison 
of alirocumab versus the other individual options of the 
usual care will be performed via exploratory subgroup 
analyses.
Safety analysis will be descriptive, based on the safety 
population (i.e. all randomised individuals who receive at 
least one dose or part of a dose of study treatment). Study 
participants will be analysed according to the treatment 
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actually received (usual care or alirocumab). The safety 
analysis will focus on the TEAE period, defined as the 
time from the first open-label dose to the last open-label 
dose of alirocumab + 70 days (10 weeks) (if randomised 
to alirocumab) or, if randomised to usual care, 70  days 
after the last usual care treatment investigational medici-
nal product has been administered or study day 225, 
whichever comes first. If the study participant is ran-
domised to usual care and the investigator has not pre-
scribed an additional lipid-lowering therapy, the date of 
the “last dose of study drug” is defined as the date of the 
last on-site study visit. Descriptive analyses will be per-
formed for I-TAQ, DM-related endpoints and other end-
points such as anti-alirocumab antibodies.
Results
Recruitment of study participants was completed in Sep-
tember 2016 with a final randomised population of 413 
individuals from 110 active sites in 14 countries (Addi-
tional file 1: Appendix S1). For the primary analysis (ali-
rocumab vs usual care), 413 individuals were randomised 
(276 alirocumab; 137 usual care); approximately 18% of 
randomised individuals were statin-intolerant. For the 
analysis of alirocumab versus fenofibrate, 72 individuals 
were randomised (48 alirocumab; 24 fenofibrate). Since 
more study participants received fenofibrate than antici-
pated, recruitment of study participants was stopped ear-
lier than scheduled, as the required sample size to ensure 
adequate statistical power had been reached.
Main study results of this clinical trial with a 24-week 
treatment period are expected in the second quarter of 
2017.
Full details of baseline characteristics, study population 
disposition and efficacy and safety results will be avail-
able in the future.
Discussion
The ODYSSEY DM-DYSLIPIDEMIA trial has been 
designed to investigate the superiority of alirocumab ver-
sus usual care in improving non-HDL-C and other lipid 
parameters in individuals with T2DM and mixed dyslipi-
daemia at high cardiovascular risk. This is the first trial 
in the ODYSSEY programme to evaluate non-HDL-C as 
a primary efficacy endpoint. Findings will supplement 
available data from the Phase 3 ODYSSEY clinical devel-
opment programme, which studied non-HDL-C as a 
secondary efficacy endpoint. Results will also expand on 
the subgroup analysis in five Phase 3 ODYSSEY placebo-
controlled trials of individuals with DM and mixed dys-
lipidaemia which showed substantial improvements in 
LDL-C and non-HDL-C levels with alirocumab that were 
similar to those in individuals with DM without mixed 
dyslipidaemia [33].
As discussed previously, non-HDL-C levels are 
believed to provide a better risk estimation of cardiovas-
cular disease than LDL-C, especially in individuals with 
DM and mixed dyslipidaemia, and statins are commonly 
used to modulate non-HDL-C levels. However, despite 
statin treatment, many individuals with DM and dyslipi-
daemia remain sub-optimally treated, and many go on to 
experience cardiovascular events [22]. A second lipid-
lowering therapy is frequently used to bring non-HDL-C 
to within the target range. Currently, there is no single 
preferred second-line treatment, and guidelines typically 
suggest an individualised approach [4, 9–12]. The ODYS-
SEY DM-DYSLIPIDEMIA study, comparing alirocumab 
with usual care (which includes other lipid-lowering 
therapies currently used to manage mixed dyslipidaemia, 
namely ezetimibe, fibrates, nicotinic acid and omega-3 
fatty acids), allows physicians participating in the study to 
make an individualised therapeutic choice for each study 
participant whose non-HDL-C remains elevated despite 
maximally tolerated statin therapy.
In addition to individuals on maximally tolerated sta-
tin therapy, this study also assessed the efficacy and safety 
of alirocumab in individuals with DM and mixed dyslipi-
daemia who are statin-intolerant or are on alternate-day 
dosing regimens of statins. Furthermore, this study is also 
powered to assess the superiority of alirocumab versus 
fenofibrate. Fenofibrate therapy, which has not defini-
tively demonstrated cardiovascular outcome benefits in 
a randomised trial setting, has been suggested to reduce 
cardiovascular risk when co-administered with a statin in 
individuals with DM with elevated TG and low HDL-C 
[16, 17, 36].
Distinct from previous studies in the ODYSSEY Phase 
3 clinical development programme, this trial will also 
measure LDL-P number and size, and Apo C-III. Indi-
viduals with T2DM are known to have a higher pro-
portion of atherogenic, small, dense LDL particles than 
those without DM. These small, dense LDL-P, which are 
more susceptible to glycation or oxidation, decrease their 
affinity for the LDL receptor (LDLR) and contribute to 
reduced LDL catabolism [2]. In a post hoc substudy of a 
Phase 2 trial, alirocumab has been shown to significantly 
reduce both LDL-C and LDL-P concentrations in hyper-
cholesterolaemic individuals without DM on stable statin 
therapy [37]. Apo C-III, an important regulator of TG 
levels, has been shown to be an independent cardiovas-
cular risk factor in individuals with DM [38]. Apo C-III 
genetic deficiencies are associated with low TG levels and 
reduced risk of coronary heart disease [39]. In a post hoc 
analysis of three Phase 2 trials, alirocumab was shown to 
reduce Apo C-III levels by 14.5–19.1% in non-diabetic 
individuals with LDL-C  ≥100  mg/dl (2.59  mmol/l) on 
stable statin therapy [40]. This effect may be a result of 
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increased clearance or reduced production of VLDL 
particles rather than an impact on Apo C-III synthesis. 
Interestingly, recent evidence suggested that Apo C-III 
might inhibit clearance of TRL through a mechanism 
closely related to LDL family receptors (i.e. LDLR and 
LDLR–related protein 1) [41]; whether alirocumab and 
PCSK9 inhibitors impact this mechanism may be an area 
of future research. Furthermore, it may be hypothesised 
that increased hepatic PCSK9 expression is involved in 
the initiation of mixed dyslipidaemia [42–44]. However, 
the blocking of the PCSK9 extracellular pathway with 
PCSK9 monoclonal antibodies does not clinically mean-
ingfully reduce plasma TG levels in the Phase 3 trials, 
though notably they were mainly conducted in normo-
triglyceridaemic subjects [45]. As statins have a greater 
TG-lowering effect in those with higher baseline TG lev-
els [17], it is of interest that this study will evaluate the 
effect of PCSK9 inhibition in patients with elevated levels 
of TGs at baseline.
There is currently high interest as to whether PCSK9 
inhibitors affect glucose homeostasis following recent 
reports suggesting a potential link between PCSK9 and 
DM [46–48]. A previous pooled analysis of 10 Phase 3 
ODYSSEY clinical trials including ~5000 individuals (fol-
lowing 24–104 weeks of follow-up) did not find evidence 
of changes in glycaemic control following treatment with 
alirocumab [32]. To expand on these findings, the ODYS-
SEY DM-DYSLIPIDEMIA study will capture changes to 
DM-related endpoints including  HbA1c, FPG, and the 
number of glucose-lowering agents. Further valuable 
information on the use of alirocumab in individuals with 
DM will be provided by the ongoing ODYSSEY DM-
INSULIN trial, which investigates alirocumab in individ-
uals with T1 and T2DM at high cardiovascular risk who 
are being treated with insulin [49]. Moreover, the recent 
discontinuation of the clinical development of bococi-
zumab, due to loss of efficacy over time and immuno-
genicity issues [25, 26], has also sparked interest in the 
development and effect of anti-drug antibodies. A pooled 
analysis of 10 ODYSSEY trials showed very low rates of 
immunogenicity with alirocumab, without loss of effi-
cacy over time [27]. Anti-alirocumab antibodies will be 
measured throughout the study to further assess immu-
nogenicity in this specific population of individuals with 
T2DM and mixed dyslipidaemia.
DM-DYSLIPIDEMIA also explores treatment accept-
ance through the I-TAQ, a patient-reported outcome 
measure [34]. Alirocumab requires patients to self-
administer the medication via subcutaneous injections, 
a treatment strategy that has previously been rarely 
used in the management of hyperlipidaemia; therefore, 
understanding patients’ perspectives about using injec-
tion treatments versus oral medications is important 
but difficult to measure with existing methods. Based 
on previous data, the majority of study participants and 
physicians have considered the alirocumab pre-filled pen 
to be easy to use, and participants have shown a willing-
ness to self-inject [50]; high rates of treatment adherence 
(~98%) have been reported with alirocumab [34]. Further 
information on treatment acceptance will be provided by 
DM-INSULIN, which investigates alirocumab in individ-
uals being treated with insulin (and hence already famil-
iar with self-injection) [49].
Conclusions
Together with the ODYSSEY DM-INSULIN study, the 
ODYSSEY DM–DYSLIPIDEMIA trial will provide valu-
able information on the efficacy and safety of alirocumab 
in individuals with DM. The large ongoing ODYSSEY 
OUTCOMES trial (NCT01663402), which randomised 
patients within 1 year post acute coronary syndrome and 
includes a significant number of patients with DM, will 
provide data on the benefit of alirocumab on cardiovas-
cular morbidity and mortality. These trials may ultimately 
help guide clinical decision-making beyond statin ther-
apy in this high-risk population.
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